Arcutis Announces CFO Succession as David Topper Retires and Latha Vairavan Steps Up

Arcutis Biotherapeutics has announced a key leadership transition as Chief Financial Officer David Topper prepares to retire on May 15, 2025. Topper, who played a pivotal role in strengthening the company’s financial standing since taking the CFO role in 2024, will pass the baton to current VP and Controller Latha Vairavan as part of a planned succession. During his tenure, Topper led impactful initiatives, including renegotiating debt terms with SLR Investment Corp. and spearheading Arcutis’ investor relations overhaul. He will remain with the company through the Q1 10-Q filing to support a seamless transition.

Stepping into the CFO role, Latha Vairavan brings over two decades of financial leadership experience in biotech, including 12 years at Amgen and nearly five at Arcutis. Her promotion underscores the company’s focus on continuity and internal growth as it expands the commercial reach of its flagship product, ZORYVE® (roflumilast). “I’m honored to step into this role at such an exciting time for Arcutis,” said Vairavan. “We’ve built incredible momentum, and I look forward to driving continued financial strength as we grow.”